Cargando…
Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity
Abnormal alteration of bone morphogenetic protein (BMP) signaling is implicated in many types of diseases including cancer and heterotopic ossifications. Hence, small molecules targeting BMP type I receptors (BMPRI) to interrupt BMP signaling are believed to be an effective approach to treat these d...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489870/ https://www.ncbi.nlm.nih.gov/pubmed/26133550 http://dx.doi.org/10.1371/journal.pone.0132221 |
_version_ | 1782379434594009088 |
---|---|
author | Alsamarah, Abdelaziz LaCuran, Alecander E. Oelschlaeger, Peter Hao, Jijun Luo, Yun |
author_facet | Alsamarah, Abdelaziz LaCuran, Alecander E. Oelschlaeger, Peter Hao, Jijun Luo, Yun |
author_sort | Alsamarah, Abdelaziz |
collection | PubMed |
description | Abnormal alteration of bone morphogenetic protein (BMP) signaling is implicated in many types of diseases including cancer and heterotopic ossifications. Hence, small molecules targeting BMP type I receptors (BMPRI) to interrupt BMP signaling are believed to be an effective approach to treat these diseases. However, lack of understanding of the molecular determinants responsible for the binding selectivity of current BMP inhibitors has been a big hindrance to the development of BMP inhibitors for clinical use. To address this issue, we carried out in silico experiments to test whether computational methods can reproduce and explain the high selectivity of a small molecule BMP inhibitor DMH1 on BMPRI kinase ALK2 vs. the closely related TGF-β type I receptor kinase ALK5 and vascular endothelial growth factor receptor type 2 (VEGFR2) tyrosine kinase. We found that, while the rigid docking method used here gave nearly identical binding affinity scores among the three kinases; free energy perturbation coupled with Hamiltonian replica-exchange molecular dynamics (FEP/H-REMD) simulations reproduced the absolute binding free energies in excellent agreement with experimental data. Furthermore, the binding poses identified by FEP/H-REMD led to a quantitative analysis of physical/chemical determinants governing DMH1 selectivity. The current work illustrates that small changes in the binding site residue type (e.g. pre-hinge region in ALK2 vs. ALK5) or side chain orientation (e.g. Tyr219 in caALK2 vs. wtALK2), as well as a subtle structural modification on the ligand (e.g. DMH1 vs. LDN193189) will cause distinct binding profiles and selectivity among BMP inhibitors. Therefore, the current computational approach represents a new way of investigating BMP inhibitors. Our results provide critical information for designing exclusively selective BMP inhibitors for the development of effective pharmacotherapy for diseases caused by aberrant BMP signaling. |
format | Online Article Text |
id | pubmed-4489870 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-44898702015-07-15 Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity Alsamarah, Abdelaziz LaCuran, Alecander E. Oelschlaeger, Peter Hao, Jijun Luo, Yun PLoS One Research Article Abnormal alteration of bone morphogenetic protein (BMP) signaling is implicated in many types of diseases including cancer and heterotopic ossifications. Hence, small molecules targeting BMP type I receptors (BMPRI) to interrupt BMP signaling are believed to be an effective approach to treat these diseases. However, lack of understanding of the molecular determinants responsible for the binding selectivity of current BMP inhibitors has been a big hindrance to the development of BMP inhibitors for clinical use. To address this issue, we carried out in silico experiments to test whether computational methods can reproduce and explain the high selectivity of a small molecule BMP inhibitor DMH1 on BMPRI kinase ALK2 vs. the closely related TGF-β type I receptor kinase ALK5 and vascular endothelial growth factor receptor type 2 (VEGFR2) tyrosine kinase. We found that, while the rigid docking method used here gave nearly identical binding affinity scores among the three kinases; free energy perturbation coupled with Hamiltonian replica-exchange molecular dynamics (FEP/H-REMD) simulations reproduced the absolute binding free energies in excellent agreement with experimental data. Furthermore, the binding poses identified by FEP/H-REMD led to a quantitative analysis of physical/chemical determinants governing DMH1 selectivity. The current work illustrates that small changes in the binding site residue type (e.g. pre-hinge region in ALK2 vs. ALK5) or side chain orientation (e.g. Tyr219 in caALK2 vs. wtALK2), as well as a subtle structural modification on the ligand (e.g. DMH1 vs. LDN193189) will cause distinct binding profiles and selectivity among BMP inhibitors. Therefore, the current computational approach represents a new way of investigating BMP inhibitors. Our results provide critical information for designing exclusively selective BMP inhibitors for the development of effective pharmacotherapy for diseases caused by aberrant BMP signaling. Public Library of Science 2015-07-02 /pmc/articles/PMC4489870/ /pubmed/26133550 http://dx.doi.org/10.1371/journal.pone.0132221 Text en © 2015 Alsamarah et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Alsamarah, Abdelaziz LaCuran, Alecander E. Oelschlaeger, Peter Hao, Jijun Luo, Yun Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity |
title | Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity |
title_full | Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity |
title_fullStr | Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity |
title_full_unstemmed | Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity |
title_short | Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity |
title_sort | uncovering molecular bases underlying bone morphogenetic protein receptor inhibitor selectivity |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489870/ https://www.ncbi.nlm.nih.gov/pubmed/26133550 http://dx.doi.org/10.1371/journal.pone.0132221 |
work_keys_str_mv | AT alsamarahabdelaziz uncoveringmolecularbasesunderlyingbonemorphogeneticproteinreceptorinhibitorselectivity AT lacuranalecandere uncoveringmolecularbasesunderlyingbonemorphogeneticproteinreceptorinhibitorselectivity AT oelschlaegerpeter uncoveringmolecularbasesunderlyingbonemorphogeneticproteinreceptorinhibitorselectivity AT haojijun uncoveringmolecularbasesunderlyingbonemorphogeneticproteinreceptorinhibitorselectivity AT luoyun uncoveringmolecularbasesunderlyingbonemorphogeneticproteinreceptorinhibitorselectivity |